Publication | Open Access

Phase Ii Study of Lenvatinib (Len), a Multi-Targeted Tyrosine Kinase Inhibitor, in Patients (Pts) with All Histologic Subtypes of Advanced Thyroid Cancer (Differentiated, Medullary and Anaplastic)

MedicineAdvanced Thyroid CancerPharmacologyThyroid DiseasePathologyPhase Ii StudyHistologic SubtypesCancer TreatmentThyroid HormoneOncologyTumor Biology